Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial

Authors:

Abstract
No abstract available
Funding Information
  • Novartis
  • Novartis
  • Novartis
  • Novartis
  • Novartis

This publication has 38 references indexed in Scilit: